This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Willerson, J. T. Articles by Perin, E. C. Search for Related Content PubMed PubMed Citation Articles by Willerson, J. T. Articles by Perin, E. C. Related Collections Related Article

(Circulation Research. 2005;97:735.)
© 2005 American Heart Association, Inc.

Editorials

Blood-Derived Progenitor Cells After Recanalization of Chronic Coronary Artery Occlusions in Humans

James T. Willerson, Edward T.H. Yeh, Yong-Jian Geng, Emerson C. Perin

From The University of Texas Health Science Center at Houston and the Texas Heart Institute, Tex.

Correspondence to Dr James T. Willerson, President, The University of Texas Health Science Center at Houston, President-Elect and Medical Director, Texas Heart Institute, 6770 Bertner (MC 3-116), Houston, TX 77030. E-mail slanier@sleh.com

See related article, pages 756–762

Key Words: stem cells • chronic coronary occlusions

An extract of the first 250 words of the full text is provided, because this article has no abstract.

The first studies to treat patients with acute ST segment elevation myocardial infarction were by Strauer et al and Zeiher et al.^1,2 In these studies, percutaneous transluminal coronary angioplasty (PTCA) was used to open the infarct related artery, and bone marrow-derived mononuclear cells or circulating endothelial progenitor cells were injected into the infarct-related arteries.^1,2 The cell-based therapy in these 2 initial studies improved coronary blood flow and segmental left ventricular (LV) function in the treated regions. Wollert et al subsequently reproduced the earlier findings in a blinded randomized study, again in patients with acute ST segment elevation myocardial infarcts (MIs).³ These 3 studies were the first to treat patients with acute ST segment elevation MIs after PTCA with cell-based therapy, and each used intracoronary injections in patients who did not have severe heart failure.

At the same time that Strauer et al and Zeiher et al were performing their initial studies in Germany (2000–2002), Texas Heart Institute cardiologists, Drs Perin and Willerson and Brazilian cardiologists led by Dr Dohmann in Rio de Janeiro, Brazil, were treating patients with chronic coronary heart disease, prior myocardial infarction, and severe heart failure with transendocardial injections of bone marrow-derived mononuclear cells using electromechanical mapping to identify sites of reversible myocardial injury.⁴ This was the initial study in the world done with cell-based therapy for patients with severe heart failure with direct transendocardial injections of bone marrow-derived mononuclear cells into the human heart. We also reported improved coronary blood flow and segmental and global LV . . . [Full Text of this Article]

Related Article:

Transplantation of Blood-Derived Progenitor Cells After Recanalization of Chronic Coronary Artery Occlusion: First Randomized and Placebo-Controlled Study

Sandra Erbs, Axel Linke, Volker Adams, Karsten Lenk, Holger Thiele, Klaus-Werner Diederich, Frank Emmrich, Regine Kluge, Kai Kendziorra, Osama Sabri, Gerhard Schuler, and Rainer Hambrecht
Circ. Res. 2005 97: 756-762. [Abstract] [Full Text] [PDF]